González Marco Antonio Cabrera, Gonçalves Ana Alice Maia, Ottino Jennifer, Leite Jaqueline Costa, Resende Lucilene Aparecida, Melo-Júnior Otoni Alves, Silveira Patrícia, Cardoso Mariana Santos, Fujiwara Ricardo Toshio, Bueno Lilian Lacerda, Santos Renato Lima, Carvalho Tatiane Furtado de, Garcia Giani Martins, Paes Paulo Ricardo de Oliveira, Galdino Alexsandro Sobreira, Chávez-Fumagalli Miguel Angel, Melo Marília Martins, Silveira-Lemos Denise, Martins-Filho Olindo Assis, Dutra Walderez Ornelas, Mosqueira Vanessa Carla Furtado, Giunchetti Rodolfo Cordeiro
Departamento de Morfologia, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil.
Laboratório de Desenvolvimento Galênico e Nanotecnologia, Escola de Farmácia, Universidade Federal de Ouro Preto (UFOP), Ouro Preto 35400-000, MG, Brazil.
Vaccines (Basel). 2023 Jan 2;11(1):111. doi: 10.3390/vaccines11010111.
Visceral leishmaniasis (VL) is a fatal disease caused by the protozoa for which dogs are the main reservoirs. A vaccine against canine visceral leishmaniasis (CVL) could be an important tool in the control of human and CVL by reducing the infection pressure of . Despite the CVL vaccine available on the market, the Brazilian Ministry of Health did not implement the use of it in their control programs. In this sense, there is an urgent need to develop more efficient vaccines. In this study, the association between two polymeric nanoformulations, (poly (D, L-lactic) acid (PLA) polymer) loading antigens, was evaluated as a potential immunobiological agent against VL using golden hamsters as an experimental model. The results indicated that no significant adverse reactions were observed in animals vaccinated with LAPSmP. LAPSmP presented similar levels of total anti- IgG as compared to LAPSmG. The LAPSmP and LAPSmG groups showed an intense reduction in liver and spleen parasitic load by qPCR. The LAPSmP and LAPSmG vaccines showed exceptional results, indicating that they may be promising candidates as a VL vaccine.
内脏利什曼病（VL）是一种由原生动物引起的致命疾病，狗是其主要宿主。一种针对犬内脏利什曼病（CVL）的疫苗可能是通过降低感染压力来控制人类和CVL的重要工具。尽管市场上有CVL疫苗，但巴西卫生部并未在其控制项目中使用。从这个意义上说，迫切需要开发更有效的疫苗。在本研究中，使用金黄仓鼠作为实验模型，评估了两种负载抗原的聚合物纳米制剂（聚（D，L-乳酸）（PLA）聚合物）作为抗VL潜在免疫生物制剂的关联性。结果表明，用LAPSmP疫苗接种的动物未观察到明显的不良反应。与LAPSmG相比，LAPSmP的总抗IgG水平相似。通过qPCR检测，LAPSmP和LAPSmG组的肝脏和脾脏寄生虫载量显著降低。LAPSmP和LAPSmG疫苗显示出优异的结果，表明它们可能是有前景的VL疫苗候选物。
